US Patent

US12213983 — Treatment of cancers using PI3 kinase isoform modulators

Method of Use · Assigned to Infinity Pharmaceuticals Inc · Expires 2035-04-26 · 9y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for treating cancers or hematologic disorders using a PI3 kinase inhibitor.

USPTO Abstract

Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.

Drugs covered by this patent

Copiktra (DUVELISIB) · Secura

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2412`	—	Copiktra
`U-2412`	—	Copiktra

Patent Metadata

Patent number: US12213983
Jurisdiction: US
Classification: Method of Use
Expires: 2035-04-26
Drug substance claim: No
Drug product claim: No
Assignee: Infinity Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.